Renée Aguiar-Lucander

Renée Aguiar-Lucander

Chief Executive Officer at HANSA BIOPHARMA AB

Net worth: 926 981 $ as of 2026-08-30

64 year
Health Technology
Commercial Services
Finance

Profile

Renée Julie Elisabet Aguiar-Lucander is currently Chief Executive Officer at Hansa Biopharma AB since 2025.
Also holds Chairman positions at Simparel, Inc. and Exenta, Inc. Serves as Director at Inventiva SA and Egalet A, Independent Director at AC Immune SA, and Director at Ral Capital Ltd. (United Kingdom), all starting in 2025 or ongoing.
Formerly Chief Executive Officer at Calliditas Therapeutics AB from 2017 to 2025.
Previously held roles including Chairman at EnXray Ltd., Director at SpineVision SAS, ImpactRx, Inc., NsGene A, Onyvax Ltd., Sophion Bioscience A, BioSilta Ltd., Danish BioVenture General Partner ApS, Calliditas Therapeutics France SAS, and SciBase Holding AB. Served as Independent Director at Zyla Life Sciences LLC, MedCap AB, and SciBase Holding AB. Held Independent Non-Executive Director position at Newron Pharmaceuticals SpA from 2006 to 2011.
Non-Executive Director at Pulmagen Therapeutics (Synergy) Ltd. Independent Director at Egalet Ltd. in 2013.
Managing Director-Corporate Finance at Lehman Brothers, Inc. (Milan Branch) in 2003.
Partner at 3i Group Plc and 3i Venture Capital.
Chief Operating Officer & Partner at Omega Fund Management UK LLP.
Education includes an MBA from INSEAD and undergraduate studies at Stockholm School of Economics.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2025-07-27 150,000 ( 0.15% ) 675 782 $ 2026-08-30
2026-06-10 51,136 ( 0.05% ) 134 999 $ 2026-08-30
2026-02-28 24,700 ( 0.01% ) 116 201 $ 2026-08-30

Renée Aguiar-Lucander active positions

CompaniesPositionStart
HANSA BIOPHARMA AB Chief Executive Officer 2025-04-23
INVENTIVA Director/Board Member 2025-05-21
AC IMMUNE SA Director/Board Member 2025-06-18
Ral Capital Ltd. (United Kingdom)
Director/Board Member -
Chairman -
Chairman -
Director/Board Member -

Former positions of Renée Aguiar-Lucander

CompaniesPositionEnd
CALLIDITAS THERAPEUTICS AB Chief Executive Officer 2024-12-31
ZYLA LIFE SCIENCES Director/Board Member 2015-06-09
░░░░░░ ░░░░ ░░░░░░░░ ░░░░░░░░░░
░░ ░░░░░░░ ░░░░░░░ ░░░░░░░ ░░░░░░ ░░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░░░░ ░░░░ ░░░░░░ ░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
See the detail of Renée Aguiar-Lucander's experience

Training of Renée Aguiar-Lucander

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

65

1st degree connections

29

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies29

Miscellaneous

Health Technology

Commercial Services

Health Technology

Health Technology

Commercial Services

Consumer Services

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Commercial Services

Finance

Health Technology

Finance

Health Technology

Commercial Services

Health Technology

Omega Fund Management UK LLP

Finance

Health Technology

Health Technology

Technology Services

Commercial Services

Technology Services

Ral Capital Ltd. (United Kingdom)

  1. Stock Market
  2. Insiders
  3. Renée Aguiar-Lucander
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!